Greatest EGFR Prevalence in Women with Adenocarcinoma with No Smoking History
the Cancer Therapy Advisor take:
Women diagnosed with adenocarcinoma who never smoked demonstrated the greatest prevalence of epidermal growth factor receptor (EGFR) mutations, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
The study included an initial dataset of 4,200 patients. In total, 4,196 of these participants were eligible—431 of which had EGFR mutations.
Results showed women had significantly greater (P <0.0001) odds of EGFR mutations compared to males (OR: 1.85; 95% C: 1.48, 2.32).
A similar trend was observed for never-smokers versus smokers (OR, 3.64; 95% CI: 2.91, 4.56), and patients with adenocarcinoma versus other histologic subtypes (OR, 2.94; 95% CI: 2.17, 4.08).
Furthermore, EGFR tyrosine kinase inhibitors (TKIs) in EGFR mutation–positive non-small cell lung cancer (NSCLC) and combination chemotherapy in EGFR mutation–negative NSCLC were determined to be the most commonly prescribed first-line systemic treatments (56.6% and 78.5%, respectively).
Women diagnosed with adenocarcinoma who never smoked demonstrated the greatest prevalence of epidermal growth factor receptor (EGFR) mutations.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL